MedTrace Logo

Imaging Study in Advanced Ovarian Cancer

NCT03808792 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-01-18

No results posted yet for this study

Summary

The aim of the study is the assessment of tumour sites critical for the achievement of optimal cytoreduction in patients with advanced ovarian cancer using Ultrasound, CT and WB-DWI/MRI. The study uses an equivalence design with a hypothesis that cases with non-resectable disease identified by Index test (Ultrasound, CT and WB-DWI MRI) are equivalent to a portion of cases identified during surgery.

Conditions

Interventions

DIAGNOSTIC_TEST

Ultrasound, CT and WB-DWI/MRI

Preoperative assessment with Ultrasound, CT and WB-DWI/MRI

Sponsors & Collaborators

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Daniela Fischerová, MD, PhD · Gynecologic Oncology Center, Department of Obstetrics and Gynecology, General University Hospital in Prague and 1st Medical Faculty of the Charles University, Prague, Czech Republic

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808792 on ClinicalTrials.gov